Free tool
FAERS Monitor: Sarclisa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761113 or its brand name (Sarclisa, Isatuximab-Irfc). Reports on generic versions are filed under their own applications.
Reports
5,800
Serious
5,382
93% of reports
Hospitalization
2,950
Death reported
767
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia524
- plasma cell myeloma408
- pneumonia386
- thrombocytopenia330
- covid-19306
- pyrexia295
- anaemia284
- infusion related reaction260
- diarrhoea251
- off label use242
- dyspnoea210
- nausea172
- drug ineffective162
- death159
- acute kidney injury157
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 20 |
| 2019 | 62 |
| 2020 | 353 |
| 2021 | 680 |
| 2022 | 1,138 |
| 2023 | 1,302 |
| 2024 | 814 |
| 2025 | 718 |
| 2026 | 707 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,359 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 408 | 38.3 | 34.9 | 14,661 |
| infusion related reactionSignal | 260 | 14.3 | 12.7 | 3,194 |
| neutropeniaSignal | 524 | 14.0 | 12.9 | 6,342 |
| thrombocytopeniaSignal | 330 | 10.7 | 9.7 | 2,909 |
| covid-19Signal | 306 | 6.3 | 5.7 | 1,378 |
| anaemiaSignal | 284 | 5.4 | 4.8 | 1,023 |
| pneumoniaSignal | 386 | 4.3 | 3.9 | 998 |
| acute kidney injurySignal | 157 | 3.7 | 3.2 | 312 |
| pyrexiaSignal | 295 | 3.1 | 2.8 | 422 |
| diarrhoea | 251 | 1.4 | 1.2 | 30 |
| dyspnoea | 210 | 1.3 | 1.2 | 19 |
| off label use | 242 | 1.0 | 0.9 | 0 |
| nausea | 172 | 0.8 | 0.7 | 10 |
| death | 159 | 0.7 | 0.6 | 27 |
| drug ineffective | 162 | 0.4 | 0.4 | 119 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.